ReviewCellular and molecular life sciences : CMLS2011
Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.
Review in Cellular and molecular life sciences : CMLS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- mRNA-Based Therapeutics in Cancer Treatment.Pharmaceutics · 2023Review
- Review
- Neo-Antigen mRNA Vaccines.Vaccines · 2020Review
- Review
- Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.Cancer immunology, immunotherapy : CII · 2020Article
- Review
- The immunoproteasome and thymoproteasome: functions, evolution and human disease.Nature immunology · 2018Review
- Peptide splicing by the proteasome.The Journal of biological chemistry · 2017Review
- Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8.Molecular medicine reports · 2015Article
- Human Tumor Antigens and Cancer Immunotherapy.BioMed research international · 2015Review
- Adoptive T cell immunotherapy for cancer.Rambam Maimonides medical journal · 2015Review
- Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.Biomolecules · 2014Review
- The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus.Cellular and molecular life sciences : CMLS · 2014Article
- The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9.The Journal of biological chemistry · 2013Article
- Pathways of antigen processing.Annual review of immunology · 2013Review
- Primer on tumor immunology and cancer immunotherapy.Journal for immunotherapy of cancer · 2013Review
- Database of T cell-defined human tumor antigens: the 2013 update.Cancer immunity · 2013Review
- Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.European journal of immunology · 2012Article
- Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.Cellular oncology (Dordrecht, Netherlands) · 2012Review
- Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.The Yale journal of biology and medicine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular definition of tumor antigens recognized by cytolytic T lymphocytes (CTL) started in the late 1980s, at a time when the MHC class I antigen processing field was in its infancy. Born together, these two fields of science evolved together and provided each other with critical insights. Over the years, stimulated by the potential interest of tumor antigens for cancer immunotherapy, scientists have identified and characterized numerous antigens recognized by CTL on human tumors. These studies have provided a wealth of information relevant to the mode of production of antigenic peptides presented by MHC class I molecules. A number of tumor antigenic peptides were found to result from unusual mechanisms occurring at the level of transcription, translation or processing. Although many of these mechanisms occur in the cell at very low level, they are relevant to the immune system as they determine the killing of tumor cells by CTL, which are sensitive to low levels of peptide/MHC complexes. Moreover, these unusual mechanisms were found to occur not only in tumor cells but also in normal cells. Thereby, the study of tumor antigens has illuminated many aspects of MHC class I processing. We review here those insights into the MHC I antigen processing pathway that result from the characterization of human tumor antigens recognized by CTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.